Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Hypoxic Ischemic Encephalopathy: early-phase trial registry
9 of 14 indexed Hypoxic Ischemic Encephalopathy trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,230 of 28,707 conditions by registered trial count.
14 US clinical trials · 9 currently recruiting · #1,230 of 28,707 conditions by registered trial count
Hypoxic Ischemic Encephalopathy: 14 US clinical trials tracked, 9 recruiting.
Hypoxic Ischemic Encephalopathy is the subject of 14 registered US clinical trials on ClinicalTrials.gov, 9 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most active sponsor is ReAlta Life Sciences, running 1 of these trials.
Enrollment posture brief
Registry condition hypoxic-ischemic-encephalopathy
OPEN 9 | RECR 64% | LATE 0 | EARLY 6 | RANK #1230 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Cardiac Rehabilitation (64% recruiting · 14 trials)
Hypoxic Ischemic Encephalopathy lists 9 open slots (64% of 14 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Hypoxic Ischemic Encephalopathy on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Hypoxic Ischemic Encephalopathy is recruiting above its size-band peers.
9 of 14 indexed trials (64.3%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Hypoxic Ischemic Encephalopathy trials is spread across many organizations.
ReAlta Life Sciences accounts for 1 of 14 trials (7.1%). 14 distinct sponsors appear on at least one study for this condition label.
-
Most Hypoxic Ischemic Encephalopathy trials plan to enrol fewer than 100 people.
Median target enrolment is 42 among the 14 trials that report a genuine target (sentinel values excluded). 10 of those (71.4%) plan for fewer than 100 participants.
-
Hypoxic Ischemic Encephalopathy research is mostly interventional.
11 interventional and 3 observational studies make up this index (78.6% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
14 total, page 1 of 1
Effects of a Physical Therapy Intervention on Motor Delay in Infants Admitted to a Neonatal Intensive Care Unit
Shirley Ryan AbilityLab
NCT05568264
A Dose Escalation Study of Levetiracetam in the Treatment of Neonatal Seizures
University of California, San Diego
NCT05610085
Healthy Little Eyes
University of Wisconsin, Madison
NCT05971446
Melatonin as a Neuroprotective Therapy in Neonates With HIE Undergoing Hypothermia
University of Florida
NCT02621944
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of RLS-0071 in Newborns With Moderate or Severe Hypoxic-Ischemic Encephalopathy Undergoing Therapeutic Hypothermia
ReAlta Life Sciences
NCT05778188
The HIEnome Study: Genome Sequencing for Perinatal HIE
Baylor College of Medicine
NCT06762795
Systemic Biomarkers of Brain Injury From Hyperammonemia
Children's National Research Institute
NCT04602325
Spinal Stimulation and Mobility Devices
University of Washington
NCT05520359
Dose Optimization of Caffeine for HIE
University of North Carolina, Chapel Hill
NCT06448780
Neonatal Seizure Registry, GEnetics of Post-Neonatal Epilepsy
University of California, San Francisco
NCT05361070
Dexmedetomidine Use in Infants Undergoing Cooling Due to Neonatal Encephalopathy (DICE Trial)
University of Utah
NCT04772222
The Impact of Holding on Stress and Bonding in Mother-Infant Pairs During Therapeutic Hypothermia
MaineHealth
NCT03837717
Therapeutic Intervention Supporting Development From NICU to 6 Months for Infants Post Hypoxic-Ischemic Encephalopathy
University of Southern California
NCT05130528
Dexmedetomidine Pharmacokinetics in Neonates During Therapeutic Hypothermia
Seattle Children's Hospital
NCT02529202
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 3 |
| Phase 2 | 3 |
Top Sponsors
Named interventions
Most-linked intervention names on Hypoxic Ischemic Encephalopathy records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Hypoxic Ischemic Encephalopathy trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Hypoxic Ischemic Encephalopathy page
14 registered trials, 9 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 9 Hypoxic Ischemic Encephalopathy trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- ReAlta Life Sciences sponsors the most Hypoxic Ischemic Encephalopathy trials on record, review their full trial history before evaluating a specific study. See ReAlta Life Sciences's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Hypoxic Ischemic Encephalopathy condition card totals 14 registered trials; most-linked intervention Dexmedetomidine Hydrochloride; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.